CSL commits to new Phase I clinical trials in Australia
CSL has progressed three new therapies into first-in-human studies in Australia. All three products are new generation, high-tech medicines based on targeted monoclonal antibody technologies.
"Translating basic medical research to a therapy ready for the marketplace can be a real challenge for our scientific community. To move one product from the early concept stage into a Phase I clinical trial is an important milestone. We are very pleased to move three projects into clinical trials over a 12-month period, all of which will be conducted in Australia. This decision speaks to the dedication of our scientists and the commitment CSL has to bringing new products to patients with unmet medical needs," said CSL Chief Scientific Officer, Dr Andrew Cuthbertson.
CSL's decision to undertake Phase I, first-in-human clinical trials in Australia is supported by a local network of world-class clinical researchers who have the skills to collaborate on early-stage trials. In addition, Australia has a regulatory environment that is supportive of early stage clinical development programs, and accessible Phase I clinical trial infrastructure.
Three New Monoclonal Antibodies
All three therapies are monoclonal antibodies with novel mechanisms of action. Each addresses important areas of unmet medical need and has the potential for multiple indications. The Phase I clinical trials will focus on proof of biological concept with a view to unlocking the full potential of these research assets.
CSL324 is an anti-GCSFR monoclonal antibody, which could be used to treat rare inflammatory diseases caused by overactive neutrophil (white blood cell) activity. CSL324 works by regulating white blood cell activity in autoimmune disease to prevent over-active neutrophils from destroying healthy tissue. The therapy may present a new treatment option for inflammatory diseases involving, for example, skin, joints and lungs. Inflammatory diseases can be debilitating and have serious quality-of-life consequences for the individuals affected. The trial will explore proof of biological concept with particular focus on identifying effective therapeutic dosing.
CSL312 is an anti-factor XIIa monoclonal antibody that is being studied for multiple indications, including Hereditary Angioedema (HAE) – a disorder that causes episodic, sometimes life-threatening attacks of swelling that can affect the face, extremities, gastrointestinal tract and upper airways. For these patients, CSL312 could reduce the frequency of dosing, with the possibility of subcutaneous administration once every two to three weeks instead of bi-weekly dosing. Other potential applications being investigated are the prevention of thrombosis – the process of blood clot formation - particularly on artificial surfaces such as cardiac implants.
CSL346 is an anti-VEGF-B monoclonal antibody that could be used to control glucose absorption in insulin-resistant patients with Type 2 diabetes, by targeting fatty acid metabolism. Type 2 diabetes is one of the fastest growing chronic diseases, affecting more than 420 million1 people globally. CSL346 may also be beneficial for diabetic nephropathy; one of the most common kidney complications associated with Type 2 diabetes.
The three therapies will be showcased today at CSL's R&D investor briefing in Sydney, and form part of a strong pipeline of prospective therapies in various stages of development.
"We anticipate that our investment in translational research – taking drug targets from benchtop to bedside – will contribute to Australia’s capacity to develop early research into commercial medicines for global markets," said Dr Cuthbertson.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance